Oryzon announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb ... 26/06/2024 Healthcare Access to innovation Rare diseases Advanced therapies Seleccionada para presentación oral. La conferencia se celebrará en Milán del 21-23 de septiembre. Partners - Oryzon Genomics
Use of biotechnology in advanced therapies and new technologies in the spanish market 03/06/2024 Healthcare Access to innovation Advanced therapies Among the most important emerging technologies are the manipulation of the microbiota, CAR-T cell therapies, and gene... Partners - KONEXIO BIOTECH
Oryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ... 03/06/2024 Healthcare Access to innovation Rare diseases Innovative drugs Advanced therapies The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients... Partners - Oryzon Genomics
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for... 24/05/2024 Healthcare Access to innovation Innovative drugs Advanced therapies it is a medicine to improve progression-free survival and overall survival in patients with metastatic pancreatic... Partners
Cellab CDMO obtains a GMP certification for advanced therapy product manufacturing 22/05/2024 Healthcare Access to innovation Personalized medicine Advanced therapies The Spanish Agency for Medicines and Health Products (AEMPS) has certified compliance with the European Union Good... Partners - Cellab
Preclinical studies validate the potential of ApTOLL to reduce inflammation and regenerate... 21/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies ApTOLL shows potential for slowing the progression of multiple sclerosis (MS) in preclinical animal studies. Partners - AptaTargets
#NewAseBioMember | “This partnership gives us the possibility to establish key contacts an... 20/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies Meet Kirsch Pharma, our new member. We talked to its Raquel Márquez Duro, Key Account Mánager de España y Portugal. AseBio - Kirsch Pharma España
#AseBioID24 | “Being present at Investor Day gives you wings to visualize, work and promot... 08/05/2024 Healthcare Access to innovation Advanced therapies Financing Hector Olabegogeaskoetxea Narbaiza, CEO of MONDRAGON Health, Silver Sponsor of AseBio Investor Day, analyzes the biotech... AseBio
Oryzon reports financial results and corporate update for quarter ended March 31, 2024 07/05/2024 Healthcare Access to innovation Rare diseases Personalized medicine Advanced therapies Financing Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD)... Partners - Oryzon Genomics
Creation of new 3D liver cell models for research 30/04/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies The main objective of the project is the creation of innovative in vitro models using microencapsulation of human liver... Partners - BeCytes Biotechnologies
